Search clinical trials for: Darunavir

Total 193 results

Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.

HIV | AIDS
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains

HIV Infections
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

HIV Infection

United States, Australia, France, United Kingdom, Belgium, Germany, Spain, Argentina, Chile, Mexico, Portugal, Malaysia, Panama, South Africa, Canada, Netherlands, Brazil, Puerto Rico, Austria, Russian Federation, Thailand, Hungary, Denmar... and more
Tibotec Pharmaceuticals, Ireland

Approved for marketing

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

HIV Infections

United States, Belgium, Germany, Taiwan, Spain, Switzerland, Mexico, Slovenia, Malaysia, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Russian Federation, Czech Republic, Puerto Rico, Thailand, Hungary, Luxembourg, Venezuela
National Jewish Health

Completed

Targeting Oxidative Stress in Chronic Beryllium Disease

Chronic Beryllium Disease

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Human Immunodeficiency Virus (HIV)

United States, Spain, South Africa
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

HIV

United States, France, United Kingdom, Germany, Taiwan, Spain, Belgium, Chile, Costa Rica, Panama, South Africa, Canada, Greece, Singapore, Argentina, Mexico, Puerto Rico, Austria, Russian Federation, Thailand, Australia, Denmark, S... and more
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
Rockefeller University
Merck Sharp & Dohme LLC; Pfizer; Aaron Diamond AIDS Research Center

Completed

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

HIV Infections

United States
McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC; CIHR Canadian HIV Trials Network

Completed

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Hepatitis C | HIV | Liver Fibrosis

Canada
ANRS, Emerging Infectious Diseases

Completed

Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients (DARULIGHT)

HIV INFECTION

France
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

HIV

United Kingdom, Germany, Denmark, Belgium, Austria, Poland, Australia, Russian Federation
Geropharm

Completed

Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)

Bioequivalence

Russian Federation
ANRS, Emerging Infectious Diseases
Gilead Sciences; Janssen Pharmaceutica

Completed

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) (2LADY)

HIV Infections | HIV

Burkina Faso, Cameroon, Senegal
ANRS, Emerging Infectious Diseases

Not yet recruiting

Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses (BI-LIGHT)

HIV Infections | HBV Coinfection
Janssen-Cilag S.p.A.

Completed

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

Human Immunodeficiency Virus; HIV
Warner Chilcott

Completed

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

Ulcerative Colitis

United States, Canada, Puerto Rico
Makerere University
University of Pittsburgh; University of Nebraska; University of Liverpool

Unknown

Darunavir and Rilpivirine Interactions With Levonorgestrel Implant (DRIVE-2)

Contraception | HIV-1-infection

Uganda
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC

Completed

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART. (ROaR+)

Cardiovascular Disease | HIV

Australia
ViiV Healthcare
Pfizer

Terminated

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (MODERN)

HIV-1

United States, Netherlands, Spain, Puerto Rico, Canada, Australia, Germany, Sweden, Poland, Portugal, Switzerland, France, Denmark, Italy, Belgium, United Kingdom, Hungary, Austria, Finland
Janssen-Cilag G.m.b.H

Completed

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)

Human Immunodeficiency Virus (HIV)

Germany
Hospital Clinic of Barcelona

Completed

Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients. (RALDAR)

Integrase Inhibitors, HIV; HIV PROTEASE INHIB

Spain
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA)

Human Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) Virus

France, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
Tibotec Pharmaceuticals, Ireland

Completed

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

HIV Infections | HIV-1

United States, France, Spain, Canada, South Africa, Argentina, Brazil, Romania
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

Healthy Volunteers

Belgium
Janssen Research & Development, LLC

Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants

Healthy

Belgium
Gilead Sciences

Terminated

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Chronic Hepatitis B

New Zealand, Korea, Republic of, Hong Kong, United States, Canada, Australia, Italy, India
University of Cape Town
Desmond Tutu HIV Centre; Wits Reproductive Health and HIV Institute

Terminated

Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers (Darifi)

HIV Infections

South Africa
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
Janssen Sciences Ireland UC

Completed

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

HIV-1 Infections

Costa Rica, Panama, South Africa, Ukraine, Malaysia, Brazil, Thailand, Guatemala
Boehringer Ingelheim

Completed

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers

HIV Infections

Germany
Boehringer Ingelheim

Terminated

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

HIV Infections

United States, Bahamas, Belgium, Canada, France, Germany, Greece, Italy, Portugal, Puerto Rico, Spain, Thailand
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Janssen Sciences Ireland UC

Completed

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

HIV-1 Infections

France, Ukraine, South Africa, United Kingdom, Argentina, Brazil, India, Spain
Janssen-Cilag Ltd.

Completed

Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

HIV-1

Taiwan
Technical University of Munich
Gilead Sciences; MUC Research GmbH

Completed

Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication

Insulin Resistance

Germany
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

HIV Infections

United States, Puerto Rico, Thailand, Botswana, Argentina, Brazil, Tanzania, South Africa
International Maternal Pediatric Adolescent AIDS...
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

HIV Infections

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

Hepatitis C

United States
University Hospital, Basel, Switzerland

Terminated

Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

AIDS-related Dementia Complex

Switzerland
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients (INROADS)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

HIV Infections | Tuberculosis

United States, Malawi, Puerto Rico, South Africa, Thailand, Zimbabwe, Brazil, Kenya, Uganda, India, Tanzania, Botswana
ViiV Healthcare
GlaxoSmithKline

Completed

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Infection, Human Immunodeficiency Virus

United States
French National Agency for Research on AIDS and...
Tibotec Pharmaceutical Limited

Completed

Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

HIV Infections

France
Sabyasachi Sen

Completed

Effect on HIV Medications on EPC Cells

AIDS

United States
Janssen Research & Development, LLC

Completed

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

Healthy

Belgium
Gilead Sciences
Janssen Research & Development, LLC

Completed

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
ANRS, Emerging Infectious Diseases

Completed

4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients (ANRS162-4D)

HIV-1 Infection

France
Kirby Institute

Completed

MARCH Central Nervous System Substudy

HIV-1 Infection

Argentina, Thailand, United Kingdom
Bristol-Myers Squibb

Withdrawn

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (SUPPRESS)

HIV

United States

Search clinical trials for: Darunavir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations